Treatment failure Maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether linezolid changes treatment failure Maximum compared with vancomycin (very low certainty).
1 finding from 1 review
Intervention not reported
Death · children and adults with acute bacterial meningitis
The intervention showed no clear difference in death (moderate certainty).
1 finding from 1 review
Intervention not reported
Neurological disability · children and adults with acute bacterial meningitis
The intervention showed no clear difference in neurological disability (low certainty).
1 finding from 1 review
Intervention not reported
Seizures · children and adults with acute bacterial meningitis
The intervention showed no clear difference in seizures (low certainty).
1 finding from 1 review
Intervention not reported
Hearing loss · children and adults with acute bacterial meningitis
The intervention probably leads to lower hearing loss (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse effects: nausea, vomiting, diarrhoea · children and adults with acute bacterial meningitis
It is very uncertain whether the intervention changes adverse effects: nausea, vomiting, diarrhoea (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse effects: gastrointestinal bleeding · children and adults with acute bacterial meningitis
The intervention showed no clear difference in adverse effects: gastrointestinal bleeding (moderate certainty).
1 finding from 1 review
Death ‐ in all participants ‐ short term · people suspected to have meningococcal disease (adults and children)
Ceftriaxone showed no clear difference in death ‐ in all participants ‐ short term compared with long‐acting (oily) chloramphenicol (moderate certainty).
1 finding from 1 review
Death ‐ in confirmed cases of meningococcal meningitis (subgroup) · people suspected to have meningococcal disease (adults and children)
Ceftriaxone showed no clear difference in death ‐ in confirmed cases of meningococcal meningitis (subgroup) compared with long‐acting (oily) chloramphenicol (moderate certainty).
1 finding from 1 review
Clinical failure ‐ in all participants ‐ short term Composite clinical criteria10 · people suspected to have meningococcal disease (adults and children)
Ceftriaxone showed no clear difference in clinical failure ‐ in all participants ‐ short term Composite… compared with long‐acting (oily) chloramphenicol (moderate certainty).
1 finding from 1 review
Clinical failure ‐ in confirmed cases of meningococcal meningitis (subgroup) Composite clinical criteria10 · people suspected to have meningococcal disease (adults and children)
Ceftriaxone showed no clear difference in clinical failure ‐ in confirmed cases of meningococcal meningitis… compared with long‐acting (oily) chloramphenicol (moderate certainty).
1 finding from 1 review
Neurological sequelae ‐ in all participants‐ short term Clinical assessment11 · people suspected to have meningococcal disease (adults and children)
Ceftriaxone showed no clear difference in neurological sequelae ‐ in all participants‐ short term Clinical… compared with long‐acting (oily) chloramphenicol (low certainty).
1 finding from 1 review
Neurological sequelae ‐ in confirmed cases of meningococcal meningitis (subgroup) Clinical assesment11 · people suspected to have meningococcal disease (adults and children)
It is very uncertain whether ceftriaxone changes neurological sequelae ‐ in confirmed cases of meningococcal… compared with long‐acting (oily) chloramphenicol (very low certainty).
1 finding from 1 review
Adverse events ‐ short term · people suspected to have meningococcal disease (adults and children)
1 finding from 1 review
All‐cause mortality · antibiotic use in acute respiratory infections
Procalcitonin algorithm leads to lower mortality compared with standard care (high certainty).
1 finding from 1 review
Treatment failure Clinical assessment3 · antibiotic use in acute respiratory infections
Procalcitonin algorithm showed no clear difference in treatment failure Clinical assessment3 compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality; · Ventilator‐associated pneumonia
Monotherapy showed no clear difference in all‐cause mortality; compared with combination therapy (moderate certainty).
1 finding from 1 review
Clinical cure · Ventilator‐associated pneumonia
It is very uncertain whether monotherapy changes clinical cure (ITT) compared with combination therapy (very low certainty).
2 findings from 1 review
Adverse events · Ventilator‐associated pneumonia
Monotherapy showed no clear difference in adverse events compared with combination therapy (moderate certainty).
1 finding from 1 review
Duration of ICU stay · Ventilator‐associated pneumonia
1 finding from 1 review